USOO863321 OB2 (12) United States Patent (10) Patent No.: US 8,633,210 B2 Charrier et al. (45) Date of Patent: *Jan. 21, 2014 (54) TRIAZOLE COMPOUNDS USEFUL AS 5,710, 158 A 1/1998 Myers et al. PROTEINKNASE INHIBITORS (Continued) (75) Inventors: Jean-Damien Charrier, Wantage (GB); FOREIGN PATENT DOCUMENTS Pan Li, Lexington, MA (US); Ronald Knegtel, Abingdon (GB); Julian DE 2458965 6, 1976 Marian Charles Golec, Faringdon E. 09: k l 3. (GB); David Bebbington, Newbury EP O3O2312 2, 1989 (GB); Hayley Marie Binch, Encinitas, GB 205.2487 1, 1981 CA (US) JP 10-130 150 5, 1998 JP 2000-026421 1, 2000 (73) Assignee: Vertex Pharmaceuticals Incorporated, wo E. gig. Cambridge, MA (US) WO 9322681 11, 1993 (*) Notice: Subject to any disclaimer, the term of this (Continued) patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS This patent is Subject to a terminal dis- Wolff et, al., “Burger's Medicinal Chemistry and Drug Discovery.” claimer. 5th Ed. Part 1, pp.975-977 (1995).* Banker, et. al., (1996), Modern Pharmaceuticals, p. 596.* (21) Appl. No.: 13/094, 183 (1980),Ivashchenko, (12), 1673-7.*et al. Khimiya Geterotsiklicheskikh Soedinenii (22) Filed: Apr. 26, 2011 (Continued) (65) Prior Publication Data Primary Examiner — Jeffrey Murray US 2012/OO71657 A1 Mar. 22, 2012 (74) Attorney, Agent, or Firm — Rory C. Stewart Related U.S. Application Data (57) ABSTRACT (62) Division of application No. 1 1/492.450, filed on Jul. This invention describes novel triazole compounds of for 25, 2006, now Pat. No. 7,951,820, which is a division mula IX: of application No. 09/953,471, filed on Sep. 14, 2001, now Pat. No. 7,115,739. (60) Provisional application No. 60/232,795, filed on Sep. R2 IX 15, 2000, provisional application No. 60/257.887, filed on Dec. 21, 2000, provisional application No. Na 60/286,949, filed on Apr. 27, 2001. us M NH (51) Int. Cl. HN N AOIN 43/54 (2006.01) R. A 6LX3/57 (2006.01) N72 CO7D 40/00 (2006.01) A CO7D 403/00 (2006.01) y 2 CO7D 413/00 (2006.01) R Z CO7D 417/00 (2006.01) CO7D 49/00 (2006.01) (52) U.S. Cl. wherein-- Z'71 is: - -nitrogen or CR 9 and Z,2 is: - -nitrogen or CH, 58 fo - - - - - ificati- - - - - -s - - - - - - - h 514/266.23:544/284 provided that at least one of Z' and Z is nitrogen; G is Ring (58) es OSSO Sea C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, See application file for complete search history. wherein said Ring C has one or two ortho substituents inde (56) References Cited p endentlyy selected from —R'; Ring9. D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected U.S. PATENT DOCUMENTS from aryl, heteroaryl, heterocyclyl or carbocyclyl; R and R' 3,133,081 A 5/1964 Lafferty are independently selected from T-R, or R and Rare taken 3,755,322 A 8, 1973 Winter et al. together with their intervening atoms to form a fused ring; R', 3,935,183 A 1/1976 Baron et al. R, and T are as described in the specification. The com 3,998,951 A 12/1976 Harnish et al. pounds are useful as protein kinase inhibitors, especially as 4,051.252 A 9/1977 Mayer et al. 4,493.726 A 1, 1985 Burdeska et al. inhibitors of GSK-3 and Aurora, for treating diseases such as 4,540,698 A 9, 1985 Ishikawa et al. diabetes, cancer, and Alzheimer's disease. 4,711,951 A 12/1987 Axen et al. 5,124,441 A 6, 1992 Carlsson et al. 22 Claims, No Drawings US 8,633,210 B2 Page 2 (56) References Cited 2003/0069248 A1 4/2003 Chakravarty et al. 2003/OO73687 A1 4/2003 Bebbington et al. U.S. PATENT DOCUMENTS 2003/0078166 A1 4/2003 Davies et al. 2003/0078275 A1 4/2003 Bebbington et al. 5,916,908 A 6, 1999 Giese et al. 2003/0O83327 A1 5/2003 Davies et al. 5,972,946 A 10, 1999 Murata et al. 2003/0O87922 A1 5/2003 Bethliel et al. 6,093,716 A 7/2000 Davis et al. 2003/0092714 A1 5/2003 Cao et al. 6,184,226 B1 2/2001 Chakravarty et al. 2003/0096813 A1 5/2003 Cao et al. 6,200,977 B1 3/2001 Cushing et al. 2003/0096816 A1 5/2003 Cao et al. 6,277,989 B1 8/2001 Chakravarty et al. 2003/0105090 A1 6/2003 Bebbington et al. 6,495,582 B1 12/2002 Hale et al. 2003. O144309 A1 7/2003 Choon-Moon 6,528,509 B1 3/2003 Hale et al. 2003/0171389 A1 9, 2003 Bemis et al. 6,528,513 B2 3/2003 Cushing et al. 2003. O187002 A1 10/2003 Mortlocket al. 6,558,657 B1 5/2003 Mandeville, III et al. 2003/0199526 A1 10/2003 Choquette et al. 6,562971 B2 5/2003 Frauenkron et al. 2003/0207873 Al 1 1/2003 Harrington et al. 6,579,983 B1 6, 2003 Batchelor et al. 2003/0225073 Al 12/2003 Bebbington et al. 6,589,958 B1 7, 2003 Frietze 2004.0002496 A1 1/2004 Bebbington et al. 39 R 38. Billy al 2004/00099812004/OOO9974 A1 1/2004 Bebbington et al. 6,613,776 B2 9/2003 Knegtelet al. 2004/OOO9996 A1 1/2004 Moon et al. 6,638,926 B2 10/2003 Davies et al. 2004/0023963 A1 2/2004 Cao et al. 6,642,227 B2 11/2003 Cao et al. 2004.0029857 A1 2/2004 Hale et al. 6,653,300 B2 11/2003 Bebbington et al. 2004.0049.032 A1 3, 2004 Charrier et al. 6,653,301 B2 11/2003 Bebbington et al. 2004/OO975O1 A1 5/2004 Bebbington et al. 6,656,939 B2 12/2003 Bebbington et al. 2004/OO97531 A1 5, 2004 Ledeboer et al. 6,660,731 B2 12/2003 Bebbington et al. 2004/O157893 A1 8/2004 Bebbington et al. 6,664.247 B2 12/2003 Bebbington et al. 2004/0214814 A1 10/2004 Bebbington et al. 6,689,778 B2 2/2004 Bemis et al. 2004/0229875 A1 11, 2004 Cao et al. 6,696.452 B2 2/2004 Davies et al. 2005, 000411.0 A1 1/2005 Bebbington et al. 6,727,251 B2 4/2004 Bebbington et al. 2005, OO38023 A1 2, 2005 Bebbington et al. 6,743,791 B2 6, 2004 Cao et al. 2005.0049246 A1 3/2005 Bemis et al. 6.825, 190 B2 11/2004 Moon et al. 2005/0228.005 A1 10, 2005 Moon et al. 6,838,464 B2 1/2005 Pease et al. 2005/0234059 A1 10, 2005 Hale et al. 6,841,579 B1 1/2005 Plowman et al. 2006/0270660 A1 11/2006 Charrier et al. 6,846,928 B2 1/2005 Bebbington et al. 2007/01791.25 A1 8/2007 Fraysse et al. 6,884,804 B2 4/2005 Choon-Moon 2007,0190634 A1 8/2007 Bebbington et al. 6,949,544 B2 9/2005 Bethliel et al. 2007,0265263 A1 11 2007 Cao et al. 6,989,385 B2 1/2006 Bebbington et al. 2008/0287444 Al 11/2008 Bebbington et al. 7,008,948 B2 3/2006 Bebbington et al. 2009, O181938 A1 T/2009 Binch et al. 7,084, 159 B2 8, 2006 Cao et al. 2009, 0221602 A1 9, 2009 Charrier et al. 7,087,603 B2 8/2006 Bebbington et al. 2010.00225O2 A1 1, 2010 Jimenez et al. 7,091,343 B2 8/2006 Bebbington et al. 2010/0022507 A1 1, 2010 Jimenez et al. 7,098,330 B2 8/2006 Bebbington et al. 2010.0137305 A1 6, 2010 Binch et al. 7,115,739 B2 10/2006 Bebbington et al. 2010/0215772 A1 8, 2010 Mortimore et al. 7,179,826 B2 2/2007 Bebbington et al. 2010/0267628 A1 10, 2010 O Harte et al. 7,253,187 B2 8, 2007 Cao et al. 2010/0310675 A1 12/2010 Binch et al. 7,304,061 B2 12/2007 Hale et al. 2010. 0317641 A1 12/2010 Mortimore et al. 7,345,054 B2 3/2008 Hale et al. 2011/0020376 A1 1, 2011 Jimenez et al. 7,361,665 B2 4/2008 Ledeboer et al. 2011/OO2O377 A1 1, 2011 Pierce et al. 7,390,815 B2 6, 2008 Davies et al. 2011/0020469 A1 1, 2011 Binch et al. 7.427,681 B2 9/2008 Bebbington et al. 2011/0021559 A1 1, 2011 Jimenez et al. 7,473,691 B2 1/2009 Davies et al. 2011, 0046104 A1 2/2011 Mortimore et al. 7,491,730 B2 2/2009 Forster et al. 2011/0060013 A1 3/2011 Mortimore et al. 7,528,142 B2 5, 2009 Binch et al. 2011 OO86856 A1 4/2011 Bebbington et al. 7,531,536 B2 5/2009 Bebbington et al. 2011/0269.732 A1 11/2011 Golec et al. 7,557,106 B2 7/2009 Charrier et al. 7,579,349 B2 8/2009 Nowak et al. FOREIGN PATENT DOCUMENTS 7.625,913 B2 12/2009 Bebbington et al. 7,691,853 B2 4/2010 Bebbington et al. 7,737,151 B2 6, 2010 Mortimore et al. W. 22:5 E. 7,820,685 B2 10/2010 Binch et al. WO 9709325 3, 1997 7,863,282 B2 1/2011 Bebbington et al.